ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology Holdings Inc. (Nasdaq: ALXO) has announced an investor conference call and webcast scheduled for July 31, 2024, at 4:30 PM EDT. The purpose of this event is to share topline data results from the Phase 2 ASPEN-06 clinical trial of evorpacept, their investigational therapy for advanced HER2-positive gastric cancer. Evorpacept is designed to block the CD47 immune checkpoint pathway.
Investors and interested parties can access the live conference call by dialing (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (international) with Conference ID 9637001. A live and archived webcast of the call, along with a slide presentation, will be available on the company's website in the News & Events section.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) ha annunciato una conferenza telefonica per investitori e un webcast fissati per il 31 luglio 2024, alle 16:30 EDT. Lo scopo di questo evento è di condividere i risultati preliminari dalla fase 2 dello studio clinico ASPEN-06 di evorpacept, la loro terapia sperimentale per il cancro gastrico avanzato positivo per HER2. Evorpacept è progettato per bloccare la via del checkpoint immunitario CD47.
Gli investitori e le parti interessate possono partecipare alla conferenza telefonica in diretta componendo il numero (800) 715-9871 (U.S./Canada) o +44.800.260.6466 (internazionale) con l'ID conferenza 9637001. Un webcast live e archiviato della chiamata, insieme a una presentazione in formato slide, sarà disponibile sul sito web dell'azienda nella sezione Notizie & Eventi.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) ha anunciado una llamada de conferencia para inversores y un webcast programado para el 31 de julio de 2024, a las 4:30 PM EDT. El propósito de este evento es compartir los resultados preliminares del ensayo clínico de fase 2 ASPEN-06 de evorpacept, su terapia en investigación para el cáncer gástrico avanzado positivo para HER2. Evorpacept está diseñado para bloquear la vía del punto de control inmunológico CD47.
Los inversores y partes interesadas pueden acceder a la llamada de conferencia en vivo marcando (800) 715-9871 (EE. UU./Canadá) o +44.800.260.6466 (internacional) con el ID de conferencia 9637001. Se podrá acceder a un webcast en vivo y archivado de la llamada, junto con una presentación en formato de diapositivas, en el sitio web de la empresa en la sección de Noticias y Eventos.
ALX Oncology Holdings Inc. (Nasdaq: ALXO)는 2024년 7월 31일 오후 4시 30분 EDT로 예정된 투자자 회의 전화 및 웹캐스트를 발표했습니다. 이 이벤트의 목적은 진행 중인 HER2 양성 위암에 대한 evorpacept 2상 ASPEN-06 임상 시험의 주요 데이터 결과를 공유하기 위함입니다. Evorpacept는 CD47 면역 체크포인트 경로를 차단하도록 설계되었습니다.
투자자 및 관심 있는 당사자는 회의 ID 9637001과 함께 (800) 715-9871(미국/캐나다) 또는 +44.800.260.6466(국제)로 전화하여 라이브 회의에 참여할 수 있습니다. 회의의 라이브 및 아카이브 웹캐스트와 슬라이드 프레젠테이션은 회사 웹사이트의 뉴스 및 이벤트 섹션에서 이용할 수 있습니다.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) a annoncé une conférence téléphonique pour les investisseurs et un webcast prévu le 31 juillet 2024 à 16h30 EDT. Le but de cet événement est de partager les résultats préliminaires de l'essai clinique de phase 2 ASPEN-06 d'evorpacept, leur thérapie expérimentale contre le cancer gastrique avancé HER2-positif. Evorpacept est conçu pour bloquer la voie du point de contrôle immunitaire CD47.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en direct en composant le (800) 715-9871 (États-Unis/Canada) ou le +44.800.260.6466 (international) avec l'ID de conférence 9637001. Un webcast en direct et archivé de l'appel, ainsi qu'une présentation en diaporama, sera disponible sur le site web de l'entreprise dans la section Actualités et Événements.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) hat eine Investorenkonferenz und einen Webcast für den 31. Juli 2024 um 16:30 Uhr EDT angekündigt. Ziel dieser Veranstaltung ist es, die vorläufigen Daten der Phase-2-Studie ASPEN-06 von evorpacept, ihrer experimentellen Therapie gegen fortgeschrittenen HER2-positiven Magenkrebs, zu teilen. Evorpacept wurde entwickelt, um den CD47-Immuncheckpoint-Weg zu blockieren.
Investoren und interessierte Parteien können über die Nummer (800) 715-9871 (USA/Kanada) oder +44.800.260.6466 (international) mit der Konferenz-ID 9637001 an der Live-Konferenz teilnehmen. Ein Live- und Archiv-Webcast des Anrufs sowie eine Präsentation in Folienformat sind auf der Unternehmenswebsite im Abschnitt Nachrichten & Veranstaltungen verfügbar.
- ALX Oncology is ready to present topline data from a Phase 2 clinical trial
- The trial focuses on evorpacept for advanced HER2-positive gastric cancer, a significant market
- The company is providing multiple access options for investors to join the call and webcast
- None.
- Conference Call and Webcast Today at 4:30 PM EDT
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.
To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live and archived webcast of the conference call, please visit the News & Events section (see “Events") of the Company’s website at www.alxoncology.com, where a slide presentation will be referenced during the event.
FAQ
What is the purpose of ALX Oncology's investor call on July 31, 2024?
What is evorpacept and what is it being developed for by ALXO?
How can investors access ALX Oncology's conference call on July 31, 2024?
What phase is the ASPEN-06 clinical trial for ALXO's evorpacept?
